Both these studies thus showed that IBAT inhibition improved biochemical and histological features of sclerosing cholangitis, indicating that this drug treatment could be potentially beneficial for human cholestatic liver disease. The gene discussed is SLC10A2; the disease is sclerosing cholangitis.